Proven Principles


With over 10 years of longitudinal data, Medial EarlySign’s data sets cover more than 20 million patient lives and 150 million patient years. They include geographically, ethnically, racially, and economically diverse populations with diverse health statuses.


EarlySign’s diverse IP portfolio including its Algo Medical Framework have been awarded patent protection across the globe.

For successful deployment in clinical practice, robust evaluation and study is a must.  Currently, there are independent papers that have been published from studies conducted in 13 clinical study sites worldwide. With clinical evidence validated and published in multiple scholarly publications, our clinical data studies have demonstrated the validity and accuracy of our models.


Medial EarlySign has developed a hardened, secure HIPAA-compliant information architecture to protect patient data security.  Additionally, internal procedures ensure high quality conduct of clinical studies in compliance with applicable international regulations and legal requirements. We safeguard the rights and well-being of participants, including privacy and confidentiality of their information, and the accuracy and completeness of the reported data.

In order to translate transformative technology from research to clinical practice, EarlySign has engaged in mutually beneficial “design partnerships” with leading healthcare institutions including Geisinger Health System, Permanente Medicine Northwest, Maccabi Health System, and others.  Combining expertise in clinical care and machine learning, these partnerships lead to the deployment of clinical solutions to identify and connect with those high-risk patients and engage with them early enough via individualized interventions that may keep them healthier for longer.